Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Sepulveda-Sanchez, JM
- Gil-Gil, M
- Alonso-Garcia, M
- Salgado, MAV
- Vicente, E
- Barroso, CM
- Sanchez, AR
- Duran, G
- De Las Penas, R
- Velasco, G
- Hernandez-Lain, A
- Hilario, A
- Martin, MN
- Benavides, M
- Oleaga, L
- Montenegro, DC
- Ruano, Y
- Sanchez-Gomez, P
- Martin-Soberon, MC
- Morales-Llombart, R
- Pachon, V
- Pineda, E
Abstract
Background The cell cycle checkpoint G1/S, dependent on cyclin-dependent kinase (CDK) 4 amplification/overexpression and retinoblastoma phosphorylation, is altered in most anaplastic oligodendrogliomas (AOs). Objective We aimed to evaluate the efficacy of palbociclib, an oral inhibitor of CDK4/6 with proven efficacy in breast cancer, in patients with AO. The primary endpoint was progression-free survival at 6 months. Patients and Methods We conducted a multicenter, open-label, phase II trial evaluating the efficacy and safety of palbociclib in patients with AO who progressed on radiotherapy and chemotherapy with histologically and molecularly confirmed grade 3 oligodendroglioma and conserved retinoblastoma protein (pRb) expression by immunohistochemistry. Patients were treated with palbociclib (125 mg/day) for 3/1 weeks on/off. Results Overall, 34 patients were enrolled across 10 hospitals in the Spanish Group of Neuro-Oncology (GEINO) study. The study was stopped early owing to the lack of efficacy, with 74% of evaluable patients progressing within 6 months, which was insufficient to consider palbociclib as an active drug in this population. Within the median follow-up of 12 months, the median progression-free survival was 2.8 months [95% confidence interval (CI) 2.6-3.1] and the median overall survival was 32.1 months (95% CI 5.1-59.2). There were no partial or complete responses; only 13 patients (38%) achieved stable disease as the best response. Palbociclib was well tolerated, with neutropenia (grade 3 or higher: 58.8%) and thrombocytopenia (grade 3 or higher: 14.7%) as the most common adverse events (AEs). Both AEs had no significant impact. Conclusion Despite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.
Datos de la publicación
- ISSN/ISSNe:
- 1776-2596, 1776-260X
- Tipo:
- Article
- Páginas:
- 613-622
- PubMed:
- 33025213
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,697 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Targeted Oncology SPRINGER
Citas Recibidas en Web of Science: 17
Documentos
- No hay documentos
Filiaciones
Keywords
- Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Piperazines; Protein Kinase Inhibitors; Pyridines; Retinoblastoma; Treatment Outcome; palbociclib; retinoblastoma protein; palbociclib; piperazine derivative; protein kinase inhibitor; pyridine derivative; adult; aged; anemia; Article; asthenia; cancer grading; cancer recurrence; cancer research; cancer survival; clinical article; clinical study; cognitive defect; confidence interval; controlled study; diarrhea; drug efficacy; drug safety; drug tolerability; dyspepsia; female; flu like syndrome; follow up; headache; hospital; human; immunohistochemistry; male; middle aged; monotherapy; multicenter study; nausea; neutropenia; oligodendroglioma; overall survival; phase 2 clinical trial; priority journal; progression free survival; seizure; Spain; thrombocytopenia; treatment response; clinical trial; oligodendroglioma; pathology; retinoblastoma; treatment outcome; tumor recurrence
Campos de Estudio
Cita
Sepulveda JM,Gil M,Alonso M,Salgado M,Vicente E,Barroso CM,Sanchez AR,Duran G,De Las Penas R,MUNOZ J,Velasco G,Hernandez A,Hilario A,Martin MN,Benavides M,Oleaga L,Montenegro DC,Ruano Y,Sanchez P,Martin MC,Morales R,Pachon V,Pineda E. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO). Target. Oncol. 2020. 15. (5):p. 613-622. IF:4,493. (2).
Portal de investigación